Companies › Alentis Therapeutics
3 active drug programs in 3 registered trials: 2 Phase 1, 1 Phase 2; Oncology, Genitourinary; next expected readout Jun 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ALE.F02 anti-CLDN1 monoclonal antibody targeting non-tight junction exposed form | CLDN1 | Phase 2 | Glomerulonephritis Rapidly Progressive | Jun 2027 |
| ALE.P02 CLDN1-targeting therapy | – | Phase 1 | Squamous Non-small-cell Lung Cancer | Feb 2028 |
| ALE.P03 anti-CLDN1 antibody-drug conjugate | – | Phase 1 | Cervical Squamous Cell Carcinoma | Apr 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06047171 | ALE.F02 | Phase 2 | Glomerulonephritis Rapidly Progressive | Genitourinary | Jun 2027 |
| NCT06747585 | ALE.P02 | Phase 1 | Squamous Non-small-cell Lung Cancer | Oncology | Feb 2028 |
| NCT07169734 | ALE.P03 | Phase 1 | Cervical Squamous Cell Carcinoma | Oncology | Apr 2029 |
–
FutureGen Biopharmaceutical (Beijing) Hangzhou Sumgen Biotech Biokin (Shanghai) Biopharmaceutical LaNova Medicines Zhejiang I-Mab Biopharma US
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.